NASDAQ:PBYI Puma Biotechnology (PBYI) Stock Price, News & Analysis → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free PBYI Stock Alerts $5.01 +0.13 (+2.66%) (As of 02:45 PM ET) Add Compare Share Share Today's Range$4.87▼$5.1150-Day Range$4.30▼$7.1152-Week Range$2.13▼$7.73Volume99,591 shsAverage Volume549,772 shsMarket Capitalization$241.53 millionP/E Ratio10.89Dividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Puma Biotechnology alerts: Email Address Puma Biotechnology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside39.4% Upside$7.00 Price TargetShort InterestBearish9.60% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.87 out of 5 starsMedical Sector454th out of 908 stocksPharmaceutical Preparations Industry203rd out of 424 stocks 3.5 Analyst's Opinion Consensus RatingPuma Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePuma Biotechnology has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.60% of the float of Puma Biotechnology has been sold short.Short Interest Ratio / Days to CoverPuma Biotechnology has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Puma Biotechnology has recently increased by 1.22%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPuma Biotechnology does not currently pay a dividend.Dividend GrowthPuma Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PBYI. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Puma Biotechnology this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for PBYI on MarketBeat in the last 30 days. This is a decrease of -95% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Puma Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Puma Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders22.70% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.29% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Puma Biotechnology are expected to remain at $0.29 per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Puma Biotechnology is 10.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.93.Price to Earnings Ratio vs. SectorThe P/E ratio of Puma Biotechnology is 10.91, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 176.78.Price to Earnings Growth RatioPuma Biotechnology has a PEG Ratio of 2.75. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioPuma Biotechnology has a P/B Ratio of 4.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. About Puma Biotechnology Stock (NASDAQ:PBYI)Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Read More PBYI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PBYI Stock News HeadlinesApril 25, 2024 | americanbankingnews.comPuma Biotechnology (PBYI) to Release Quarterly Earnings on ThursdayApril 24, 2024 | nasdaq.comPBYI Crosses Above Average Analyst TargetApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? April 19, 2024 | investorplace.com7 Stocks Under $15 Predicted to Boom in the Next 2 YearsApril 18, 2024 | businesswire.comPuma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial ResultsApril 18, 2024 | americanbankingnews.comPuma Biotechnology (NASDAQ:PBYI) Stock Crosses Above 200-Day Moving Average of $4.46April 8, 2024 | finance.yahoo.comPuma Biotechnology (NASDAQ:PBYI) shareholders have earned a 93% return over the last yearApril 3, 2024 | businesswire.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? March 22, 2024 | finance.yahoo.comDo Puma Biotechnology's (NASDAQ:PBYI) Earnings Warrant Your Attention?March 20, 2024 | markets.businessinsider.comPuma Biotechnology: FDA Allows To Proceed With Clinical Development Of AlisertibMarch 20, 2024 | finance.yahoo.comPuma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast CancerMarch 2, 2024 | markets.businessinsider.comBuy Rating on Puma Biotechnology Amid Financial Challenges and Drug Advancement ProspectsMarch 2, 2024 | finance.yahoo.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Shares Could Be 47% Below Their Intrinsic Value EstimateMarch 2, 2024 | seekingalpha.comPuma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | businesswire.comPuma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | finance.yahoo.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)February 27, 2024 | businesswire.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)February 22, 2024 | finance.yahoo.comPuma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care ConferenceFebruary 22, 2024 | businesswire.comPuma Biotechnology to Participate in a Panel Discussion at TD Cowen's 44th Annual Health Care ConferenceFebruary 21, 2024 | msn.comPuma Biotech (PBYI) Is Up 23.01% in One Week: What You Should KnowFebruary 15, 2024 | finance.yahoo.comPuma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial ResultsFebruary 15, 2024 | businesswire.comPuma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial ResultsFebruary 13, 2024 | wsj.comPuma Biotechnology Inc.February 13, 2024 | finance.yahoo.comPuma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung CancerFebruary 9, 2024 | msn.comPBYI vs. AMGN: Which Stock Should Value Investors Buy Now?February 7, 2024 | finance.yahoo.comImmunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock UpSee More Headlines Receive PBYI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/26/2024Next Earnings (Confirmed)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PBYI CUSIPN/A CIK1401667 Webwww.pumabiotechnology.com Phone(424) 248-6500Fax424-248-6501Employees185Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+43.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.46 Trailing P/E Ratio10.61 Forward P/E Ratio16.83 P/E Growth2.92Net Income$21.59 million Net Margins9.16% Pretax Margin9.62% Return on Equity58.21% Return on Assets10.40% Debt Debt-to-Equity Ratio1.23 Current Ratio1.57 Quick Ratio1.50 Sales & Book Value Annual Sales$235.60 million Price / Sales1.00 Cash Flow$0.66 per share Price / Cash Flow7.37 Book Value$1.12 per share Price / Book4.36Miscellaneous Outstanding Shares48,210,000Free Float37,264,000Market Cap$235.26 million OptionableOptionable Beta1.28 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Alan H. Auerbach (Age 54)Founder, Chairman, President, CEO & Secretary Comp: $1.74MMr. Maximo F. Nougues (Age 55)CFO & Principal Accounting Officer Comp: $781.47kDr. Alvin F. Wong Pharm.d. (Age 71)Chief Scientific Officer Comp: $809.69kMr. Douglas Hunt B.Sc. (Age 59)FRAPS, Senior Vice President of Regulatory Affairs, Pharmacovigilance, Medical Affairs & Law Comp: $632.65kMr. Jeffrey Jerome Ludwig (Age 58)Chief Commercial Officer Comp: $916.85kMr. Mariann OhanesianSenior Director of Investor RelationsMore ExecutivesKey CompetitorsXBiotechNASDAQ:XBITXeris BiopharmaNASDAQ:XERSVerastemNASDAQ:VSTM23andMeNASDAQ:ME2seventy bioNASDAQ:TSVTView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Sold 14,894 shares on 4/24/2024Ownership: 0.145%Rice Hall James & Associates LLCSold 189,764 shares on 4/23/2024Ownership: 0.291%Great Point Partners LLCBought 1,093,273 shares on 2/15/2024Ownership: 2.298%Crestline Management LPBought 2,135 shares on 2/12/2024Ownership: 0.073%Jump Financial LLCBought 32,510 shares on 2/7/2024Ownership: 0.120%View All Insider TransactionsView All Institutional Transactions PBYI Stock Analysis - Frequently Asked Questions Should I buy or sell Puma Biotechnology stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PBYI shares. View PBYI analyst ratings or view top-rated stocks. What is Puma Biotechnology's stock price target for 2024? 1 brokers have issued twelve-month price objectives for Puma Biotechnology's shares. Their PBYI share price targets range from $7.00 to $7.00. On average, they predict the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 39.4% from the stock's current price. View analysts price targets for PBYI or view top-rated stocks among Wall Street analysts. How have PBYI shares performed in 2024? Puma Biotechnology's stock was trading at $4.33 at the beginning of 2024. Since then, PBYI shares have increased by 15.9% and is now trading at $5.02. View the best growth stocks for 2024 here. When is Puma Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our PBYI earnings forecast. How can I listen to Puma Biotechnology's earnings call? Puma Biotechnology will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Puma Biotechnology's earnings last quarter? Puma Biotechnology, Inc. (NASDAQ:PBYI) announced its quarterly earnings results on Thursday, February, 29th. The biopharmaceutical company reported $0.26 EPS for the quarter, missing the consensus estimate of $0.33 by $0.07. The biopharmaceutical company earned $72.20 million during the quarter, compared to the consensus estimate of $73.22 million. Puma Biotechnology had a net margin of 9.16% and a trailing twelve-month return on equity of 58.21%. What guidance has Puma Biotechnology issued on next quarter's earnings? Puma Biotechnology issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $214.0 million-$225.0 million, compared to the consensus revenue estimate of $244.7 million. What other stocks do shareholders of Puma Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and Who are Puma Biotechnology's major shareholders? Puma Biotechnology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (0.29%) and Assenagon Asset Management S.A. (0.15%). Insiders that own company stock include Alan H Auerbach, Alvin F Wong, Ann Calby Miller, Douglas M Hunt, Langley Steinert, Maximo F Nougues, Michael Patrick Miller and Troy Edward Wilson. View institutional ownership trends. How do I buy shares of Puma Biotechnology? Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PBYI) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressThe only accurate crypto trading system I know …Weiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
